Led · Series B · Jun 2026

Aluksen designs analogue, mixed-signal, and optoelectronic integrated circuits targeting optical communication and interconnect markets such as long-haul core networks, data-centre interconnect (DCI), 5G aggregation and access, and fibre-to-the-home. Its chip lineup includes MZM/EML/DML driver chips, TIA transimpedance amplifiers, and NRZ and PAM4 clock and data recovery chips, covering speeds from 10Gbps to 800Gbps. The company is pursuing optical-electronic integration as a strategic technical direction and raised a 100M CNY Series B extension to support that push. The funding round was led by Green Pine Capital with Wuxi Industrial Capital participating. Aluksen operates in a competitive market dominated by established analogue chip players and faces industry headwinds including export controls and supply-chain pressures highlighted in coverage.

Participated · Series A · Jan 2026

Founded at the end of 2020 in Shenzhen, Signet Therapeutics has built a proprietary organoid disease-modeling and AI-driven drug discovery platform aimed at solving unmet needs in diffuse gastric cancer, liver cancer, lung cancer and other metastatic solid tumors. Its lead asset, SIGX1094, is positioned as the world’s first targeted drug for diffuse gastric cancer; it holds both FDA and NMPA INDs, FDA Orphan Drug and Fast Track designations, and is currently in a Phase I study at Peking University Cancer Hospital while funds are earmarked to launch a global Phase II trial. The second pipeline, SIGX2649, is a pan-TEAD inhibitor targeting the Hippo pathway and is preparing for simultaneous China-U.S. IND filings and a Phase I initiation. Overall, the company is advancing four first-in-class programs and continues to expand its organoid platform to support internal and partnered drug discovery. The founding team hails from Harvard, MIT, Dana-Farber and other top institutions, and has published over 20 high-impact papers in Nature, Nature Medicine and Cancer Cell. To date, Signet Therapeutics has secured approximately RMB 300 million in funding and grants and holds more than 40 core patents, underlining a solid financial and intellectual-property foundation for future growth.

Participated · Equity · Aug 2021

中慧元通 is a biotechnology company engaged in vaccine research and development, regulatory filing, industrialization and commercial sales. The company has obtained clinical approvals for four Class I new‑drug candidates: pediatric and adult quadrivalent influenza virus subunit vaccines, a recombinant varicella‑zoster (shingles) vaccine, and a 9‑valent recombinant human papillomavirus (HPV) vaccine; it also holds a Class‑IX clinical approval for a 23‑valent pneumococcal polysaccharide vaccine. Its quadrivalent influenza subunit vaccine is developed with the company’s patented technology, which the article describes as delivering high purity and good safety and being especially suitable for children and the elderly. The article cites WHO’s 2018–2019 northern‑hemisphere recommended quadrivalent vaccine components in describing the product. Company activities explicitly cover R&D, registration submissions, industrialization and sales. The report also notes the company completed a Pre‑IPO financing round of more than CNY 600 million.

Participated · Series B · May 2021

Duality Biologics focuses on developing novel-modality drugs for oncology and autoimmune diseases, with an internal pipeline of nearly 10 best-in-class and first-in-class bispecific antibodies and ADCs. The company has built a next-generation ADC platform with global intellectual property and several candidates validated in preclinical development. Several drug candidates are at the IND stage. DualityBio plans to expand its pipeline through internal R&D as well as strategic in-licensing, out-licensing, and research collaborations globally. The recently completed Series B will fund preclinical research, clinical trials, and pipeline expansion. The company was founded in January 2020 and operates with an international team across China and the United States led by founder and CEO Dr. John Zhu.

Participated · Series A · May 2021

Akrostar Technology, founded in June 2020, develops and offers intellectual property (IP) to chipmakers in areas long dominated by foreign players. The company has quickly brought advanced IP products and services to market. Over the past year it has raised nearly CNY1 billion (about USD155.6 million) and has exceeded its 2021 sales target. Akrostar secured over CNY500 million (USD77.8 million) in its Series A round to support growth. The proceeds will be used to attract cutting‑edge R&D talent and accelerate product roll‑out. Chairman and Co‑CEO Zeng Keqiang said industry recognition gives the firm confidence to strive to empower China’s integrated circuit industry, and Gaorong partner Yue Bin highlighted the importance of IP to China’s chip design sector.